Therefore, our current study and these reports highlighted above suggest that ALS is a neurodegenerative disease characterized by systemic NAD+ deficiency that can benefit from NAD+ supplementation and/or SIRT3 activation. The gene discussed is SIRT3; the disease is amyotrophic lateral sclerosis.